Exscientia is a trailblazing AI-driven precision medicine company that is redefining the landscape of drug discovery and development. Based in the United Kingdom, Exscientia is committed to discovering, designing, and developing the best possible drugs in the fastest and most effective manner.

The company has developed a first-of-its-kind functional precision oncology platform that successfully guides treatment selection and improves patient outcomes in a prospective interventional clinical study. This platform also enables the progression of AI-designed small molecules into the clinical setting.

Exscientia’s internal pipeline is focused on leveraging their precision medicine platform in oncology, while their partnered pipeline broadens their approach to other therapeutic areas. By pioneering a new approach to medicine creation, Exscientia is ensuring that the best ideas of science can rapidly become the best medicines for patients.